Procter & Gamble Health
- Market cap
- ₹ 8,377 Cr.
- P/E
- 25x
- P/B
- 16.02x
- 52-week range
- 4,707 – 6,975
- ROE
- 62%
- ROCE
- 84%
- Dividend yield
- 3.1%
- Debt / equity
- 0.02
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Procter & Gamble Health Limited is an India-based multinational consumer goods company. The Company is focused on manufacturing and marketing of over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle. The Company is engaged in the manufacturing and selling of healthcare products, such as vitamins, minerals and supplements. Patients are end consumers of the products. The Company’s distribution channels (direct and indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. The Company’s brands include Polybion, Cosome, Evion, Neurobion, Seven Seas, Nasivion, and Livogen. Cosome is a medicine which is used to help relieve dry coughs and related congestion symptoms. Evion is a Vitamin E capsules. The Seven Seas is a pure vitamin rich cod-liver oil. Neurobion offers a range of neurotropic supplements. Its products are sold in about 180 countries and territories throughout the world.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Procter & Gamble Health against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)25 against a typical 33.2: cheaper than most peers (1st = cheapest).81st of 220
- Sales growth+7.4% against a typical +15.6% from a year earlier.124th of 197
- Profit growth+45.5% against a typical +18.9% from a year earlier.56th of 160
- Share price, 3 months−15.5% against a typical −0.7%.166th of 200
- Size₹ 8,377.2 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).44th of 199
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 2 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 6 Aug 2026 | Financial Results | To consider and approve the financial results for the quarter ended Jun 30, 2026 |
| 26 May 2026 | Financial Results/Dividend | To consider and approve the audited financial statements for the financial year ended March 31, 2026, and recommend final dividend, if any. |
| 6 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 5 Nov 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2025 and dividend |
| 1 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 29 May 2025 | Financial Results/Dividend | To consider and approve the audited financial results for the financial year ended March 31, 2025 and recommend dividend, if any. |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 305 | 310 | 252 | 284 | 313 | 310 | 311 | 339 | 325 | 374 | 370 | 364 |
| Expenses | 216 | 208 | 185 | 236 | 199 | 186 | 230 | 248 | 205 | 263 | 235 | 264 |
| Operating Profit | 89 | 102 | 67 | 48 | 114 | 123 | 81 | 90 | 120 | 110 | 136 | 100 |
| OPM % | 29% | 33% | 27% | 17% | 36% | 40% | 26% | 27% | 37% | 30% | 37% | 27% |
| Other Income | 6 | 5 | 2 | −18 | 3 | 4 | 3 | 4 | 5 | 4 | 4 | 36 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 6 | 7 | 7 | 7 | 6 | 6 | 5 | 5 | 6 | 6 | 6 | 6 |
| Profit before tax | 88 | 100 | 63 | 23 | 111 | 122 | 79 | 89 | 119 | 109 | 133 | 129 |
| Tax % | 26% | 28% | 26% | 26% | 26% | 25% | 22% | 25% | 26% | 29% | 29% | 26% |
| Net Profit | 66 | 72 | 47 | 17 | 82 | 91 | 61 | 66 | 89 | 78 | 95 | 96 |
| EPS in Rs | 39.5 | 43.42 | 28.05 | 10.11 | 49.6 | 54.76 | 36.86 | 39.87 | 53.34 | 46.74 | 56.99 | 57.92 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 4%
- 5 Years
- 1%
- 3 Years
- 8%
- TTM
- 13%
- 10 Years
- 20%
- 5 Years
- 5%
- 3 Years
- 19%
- TTM
- 11%
- 10 Years
- 23%
- 5 Years
- 2%
- 3 Years
- 3%
- TTM
- —
- 10 Years
- 31%
- 5 Years
- 35%
- 3 Years
- 43%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Procter & Gamble Health | ₹ 5,405.00 | ₹ 8,377 Cr. | 25x | 16x | 62% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Shashank Srowthy
- Chief Financial Officer, Additional Executive Director
- Zeal Bhavin Rupani
- Compliance Officer, Company Secretary
- Milind Thatte
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.